ImageneBio, Inc.IMAEarnings & Financial Report
ImageneBio, Inc. is a clinical-stage biotechnology company specializing in the development of precision oncology therapies and targeted radiopharmaceuticals for hard-to-treat cancers. It primarily serves the North American healthcare market, with a core focus on advancing personalized treatment options matched to patients’ unique genomic profiles.
IMA Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-26.6M
Net Profit
$-24.8M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-2.91
ImageneBio, Inc. Q3 FY2025 Financial Summary
ImageneBio, Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-24.8M (down 678.5% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-24.8M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
ImageneBio, Inc. Annual Revenue by Year
ImageneBio, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $9.2M).
ImageneBio, Inc. Quarterly Revenue & Net Profit History
ImageneBio, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-24.8M | N/A |
| Q1 FY2025 | $800.0K | — | $-6.1M | -759.6% |
| Q3 FY2024 | $3.5M | +195.4% | $-3.2M | -90.9% |
| Q4 FY2023 | $658.0K | -87.9% | N/A | N/A |
| Q3 FY2023 | $1.2M | -81.5% | $-17.3M | -1463.5% |
| Q2 FY2023 | $2.0M | +424.6% | $-17.1M | -854.0% |
| Q1 FY2023 | $5.3M | +57.0% | $-14.2M | -267.6% |
| Q4 FY2022 | $5.5M | -73.0% | $-14.1M | -258.7% |
Income Statement
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q3 2024 | Q1 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.5M | $5.3M | $2.0M | $1.2M | $658000 | $3.5M | $800000 | $0 |
| YoY Growth | -73.0% | 57.0% | 424.6% | -81.5% | -87.9% | 195.4% | N/A | N/A |
Balance Sheet
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q3 2024 | Q1 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $172.3M | $152.4M | $171.8M | $215.3M | $192.1M | $149.0M | $130.8M | $160.9M |
| Liabilities | $25.3M | $17.4M | $15.1M | $28.1M | $22.3M | $14.8M | $12.6M | $21.0M |
| Equity | $147.0M | $135.0M | $156.7M | $155.3M | $-126.1M | $-152.8M | $-169.6M | $139.8M |
Cash Flow
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q3 2024 | Q1 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-17.7M | $-19.8M | $-18.1M | $-20.0M | $-79.7M | $13.0M | $-10.6M | $-26.6M |